Human participants and genotyping data included in the study
| Sample source | N | Genotyping platform | Ancestry | Phenotypes/notes |
|---|---|---|---|---|
| BIOJUME (Shakeshaft et al. 2022) JME Individuals | 624 | Illumina Omni 2.5 | European | EUR ethnicity defined as within 6 SD of 1KG EUR (PCA) |
| Panjwani et al. 2016 | 259 | Illumina Omni 2.5 | European | Includes ESES (N = 73), RE (n = 143), MAE (n = 43) |
| Panjwani et al. 2016 | 118 | Human OmniExpress BeadChip | European | Includes CAE (n = 88), JAE (n = 30) |
| BIOJUME BIS score substudy | 324 | Illumina Omni 2.5 | European | JME individuals with complete BIS scores and seizure data |
| UK Biobank (UKBB) | 3000 | Axiom Array | White British | Random unrelated controls, filtered to exclude individuals with epilepsy |
| Canadian Gene Modifier Study (CGMS) | 1958 | Illumina 610 Quad/660W/Omni 2.5 | European | Cystic fibrosis–related diabetes |
[i] (1KG) 1000 Genomes Project, (BIOJUME) Biology of Juvenile Myoclonic Epilepsy, (BIS) Barratt impulsiveness scale, (CAE) childhood absence epilepsy, (ESES) electrical status epilepticus in sleep, (EUR) European, (JAE) juvenile absence epilepsy, (JME) juvenile myoclonic epilepsy, (MAE) myoclonic–atonic epilepsy, (PCA) principal component analysis, (RE) rolandic epilepsy, (SD) standard deviation.